Cybin Inc. Strengthens Scientific Advisory Board with Biotech Luminaries
summarizeSummary
Cybin Inc. (Helus Pharma) appointed Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, significantly enhancing its scientific expertise and credibility for pipeline advancement.
check_boxKey Events
-
Dr. Robert Langer Joins Scientific Advisory Board
Dr. Robert Langer, a globally recognized leader in biotechnology and drug delivery, co-founder of Moderna, and holder of over 1,500 patents, has been appointed to the Scientific Advisory Board. His involvement lends significant scientific credibility and strategic insight to the company's drug development efforts.
-
Dr. Stephen Brannan Appointed to Advisory Board
Dr. Stephen Brannan, a physician-scientist with extensive expertise in CNS therapeutics and former Chief Medical Officer at Karuna Pharmaceuticals, also joins the Scientific Advisory Board. His experience in advancing CNS programs through clinical development is crucial for Cybin's pipeline.
-
Strengthens Pipeline Development
These appointments are intended to strengthen the company's commitment to advancing its pipeline, which includes HLP003 in Phase 3 for major depressive disorder (with Breakthrough Therapy Designation) and HLP004 in Phase 2 for generalized anxiety disorder.
auto_awesomeAnalysis
Cybin Inc., operating as Helus Pharma, has significantly bolstered its Scientific Advisory Board with the addition of Dr. Robert Langer, a world-renowned leader in biotechnology and co-founder of Moderna, and Dr. Stephen Brannan, a seasoned CNS clinical development expert. For a clinical-stage pharmaceutical company, attracting individuals of this caliber provides a substantial boost to scientific credibility, drug development strategy, and investor confidence. This strategic move, coming just three days after the departure of CEO Michael Cola, provides a strong positive signal regarding the company's commitment to its pipeline, including HLP003 in Phase 3 and HLP004 in Phase 2, and reinforces its scientific foundation.
At the time of this filing, HELP was trading at $5.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $4.29 to $9.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.